<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029029</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069180</org_study_id>
    <secondary_id>RITA-201-00</secondary_id>
    <secondary_id>MAYO-IRB-O-1223-00</secondary_id>
    <secondary_id>MDA-ID-01534</secondary_id>
    <secondary_id>RITA-IDE-G000177</secondary_id>
    <nct_id>NCT00029029</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases</brief_title>
  <official_title>RF Ablation of Painful Metastases Involving Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells&#xD;
      and may help to relieve pain caused by bone metastases.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in relieving&#xD;
      pain in patients who have bone metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of radiofrequency ablation, in terms of pain relief at 4 weeks,&#xD;
           in patients with painful bone metastases.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Compare the change in pain interference with daily life and analgesic use at 4 weeks vs&#xD;
           baseline in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to recurrence of worst pain in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive radiofrequency ablation (RFA) to targeted tumor(s) on day 0 (multiple tumors&#xD;
      may receive ablation in multiple sessions). Patients who achieve a reduction in worst pain of&#xD;
      at least 2 points within 4-8 weeks but experience recurring pain at the RFA site or are&#xD;
      diagnosed with a new painful lesion within 4-24 weeks receive 1 additional treatment to the&#xD;
      recurring or new site.&#xD;
&#xD;
      Pain (using the Brief Pain Inventory scale of 0-10), analgesic use, and quality of life are&#xD;
      assessed at baseline, on day 1, weekly for 4 weeks, and then every 2 weeks for 20 weeks.&#xD;
&#xD;
      Patients are followed for 6 months beyond the last RFA treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2000</start_date>
  <completion_date type="Actual">October 24, 2002</completion_date>
  <primary_completion_date type="Actual">October 24, 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Metastatic Cancer</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pain therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed bone metastases&#xD;
&#xD;
          -  Pain refractory to non-opioid analgesic medication and radiotherapy OR&#xD;
&#xD;
          -  Patient is considered a poor candidate for opioid analgesics or radiotherapy&#xD;
&#xD;
          -  Initial worst pain score within the past 24 hours at least 4 on a scale of 0-10&#xD;
&#xD;
          -  Tumors deemed accessible for radiofrequency ablation&#xD;
&#xD;
          -  No evidence of impending fracture in weight-bearing bones (more than 50% loss of&#xD;
             cortical bone)&#xD;
&#xD;
          -  Tumors must be more than 1 cm from critical structures including:&#xD;
&#xD;
               -  Spinal cord, brain, or other critical nerve structures&#xD;
&#xD;
               -  Large abdominal vessel (e.g., aorta or inferior vena cava)&#xD;
&#xD;
               -  Bowel or bladder&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  INR less than 1.5&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 days since prior aspirin, ibuprofen, or other nonsteroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. William Charboneau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone metastases</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

